Aigen Investment Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Aigen Investment Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,109	Closed	-$207K	–	1226
2021 Q3	$207K	Sell	3,109 -2,632	-46%	-$187K	0.04%	416
2021 Q2	$448K	Buy	5,741 +1,288	+29%	+$95.2K	0.08%	251
2021 Q1	$421K	Sell	4,453 -834	-16%	-$99.2K	0.06%	327
2020 Q4	$644K	Buy	5,287 +5,202	+6,120%	+$570K	0.08%	313
2020 Q3	$7K	Buy	+85	New	+$5.92K	﹤0.01%	803

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Aigen Investment Management's TPTX Position: Q4 2021 in Review

Aigen Investment Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 3,109 shares — an estimated $207K sold.

Aigen Investment Management first reported a position in TPTX in Q3 2020 and held it in 5 quarters. The position peaked at $644K in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Aigen Investment Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Aigen Investment Management sold 3,109 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $207K.
Aigen Investment Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Aigen Investment Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $644K in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Aigen Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.